Check my new article about Paclitaxel-Eluting Stent written through collaboration with dr. Farhat Fouladvant.Is Paclitaxel-Eluting Stent Use Justified by an Adequate Risk Profile
Is Paclitaxel-Eluting Stent Use Justified by an Adequate Risk Profile?
WEBINAR: Sirolimus-coated balloons, an appraisal on its potential advantages over paclitaxel
Watch this roundtable discussion if you want:
- To learn and understand how and where to use a Sirolimus DCB in current practice
- To see clinical evidence and results for the treatment of patients with Sirolimus DCB
- To see the potential advantages of using the Sirolimus over Paclitaxel
Speakers: Antonio Colombo, Bernardo Cortese, Sandeep Basavarajaiah
Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective
About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.
After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.
Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.
Today we are presenting the following one:
“The hypothesis of an increased mortality following paclitaxel coated device use in peripheral vascular interventions (and the emerging era of meta-analysis based evidence)” 22.10.19